Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that is characterized by a complex immune response. Its heterogenic etiology translates into complex pathogenesis with variable types of disease manifestations and a miscellaneous range of disease progression. In most cases but not all the clinically isolated syndrome (CIS) as the first single clinical event preludes a clinically definite MS (CDMS). MS is classified into four main types of clinical courses: relapsing-remitting (RR), primary progressive (PP), secondary progressive (SP), and progressive-relapsing (PR). RRMS is the most common type of disease course and is defined by relapses of active disease and phases of remission within which the patient recovers. In most cases RRMS turns at one point into a SPMS form.
Until now there are no clear objective clinical parameters defining or predicting the type of clinical course, important hallmarks of disease progression, such as conversion to a CDMS or the switch from RRMS to SPMS, onset of relapses/remission, the expected malignancy of the individualâs MS, or the patients possible reaction to treatments Paap BK et al. Molecular Biomarkers in Multiple Sclerosis.
Journal of multiple sclerosis supports this multiple sclerosis research through our publications and original research articles.
Last date updated on June, 2014